Inozyme Pharma, Inc. (NASDAQ:INZY) Receives Consensus Rating of “Buy” from Analysts
Shares of Inozyme Pharma, Inc. (NASDAQ:INZY – Get Free Report) have earned an average rating of “Buy” from the eight ratings firms that are presently covering the company, MarketBeat Ratings reports. Eight research analysts have rated the stock with a buy rating. The average 12 month price objective among brokerages that have updated their coverage […]
Shares of Inozyme Pharma, Inc. (NASDAQ:INZY – Get Free Report) have earned an average rating of “Buy” from the eight ratings firms that are presently covering the company, MarketBeat Ratings reports. Eight research analysts have rated the stock with a buy rating. The average 12 month price objective among brokerages that have updated their coverage […]
